1. Copaxone® (glatiramer acetate injection) . Highlights of prescribing information. July 2020. Available at: https://www.copaxone.com/globalassets/copaxone/prescribing-information.pdf (Last accessed 29 October 2021).
Google Scholar2. Boster, AL, Ford, CC, Neudorfer, O, et al. Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis. Expert Rev Neurother 2015; 15: 575–586.
Google Scholar | Crossref | Medline3. Khan, O, Rieckmann, P, Boyko, A, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol 2013; 73: 705–713.
Google Scholar | Crossref | Medline | ISI4. Khan, O, Rieckmann, P, Boyko, A, et al. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study. Mult Scler 2017; 23: 818–829.
Google Scholar | SAGE Journals | ISI5. Wolinsky, JS, Borresen, TE, Dietrich, DW, et al. GLACIER: an open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 2015; 4: 370–376.
Google Scholar | Crossref | Medline6. Cutter, G, Veneziano, A, Grinspan, A, et al. Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS. Mult Scler Relat Disord 2019; 33: 13–21.
Google Scholar | Crossref | Medline7. Cutter, G, Veneziano, A, Grinspan, A, et al. Satisfaction and adherence with glatiramer acetate 40 mg/mL TIW in RRMS after 12 months, and the effect of switching from 20 mg/mL QD. Mult Scler Relat Disord 2020; 40: 101957.
Google Scholar | Crossref | Medline8. Ziemssen, T, Ashtamker, N, Rubinchick, S, et al. Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis. Expert Opin Drug Saf 2017; 16: 247–255.
Google Scholar | Medline | ISI9. Lublin, F, Cofield, S, Cutter, G, et al. Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: efficacy and safety results up to 7 years. Mult Scler Relat Disord 2017; 18: 95–102.
Google Scholar | Crossref | Medline10. Kalincik, T, Diouf, I, Sharmin, S, et al. Effect of disease-modifying therapy on disability in relapsing-remitting multiple sclerosis over 15 years. Neurology 2021; 96: e783–e797.
Google Scholar | Crossref | Medline11. Copaxone® (glatiramer acetate injection) . EMA summary of product characteristics. August 2021. Available at: https://www.medicines.org.uk/emc/product/7046/smpc#gref (Last accessed 29 October 2021).
Google Scholar12. Sormani, MP, Bruzzi, P. Can we measure long-term treatment effects in multiple sclerosis? Nat Rev Neurol 2015; 11: 176–182.
Google Scholar | Crossref | Medline | ISI